APA
Holkova B., Zingone A., Kmieciak M., Bose P., Badros A. Z., Voorhees P. M., Baz R., Korde N., Lin H., Chen J., Herrmann M., Xi L., Raffeld M., Zhao X., Wan W., Tombes M. B., Shrader E., Weir-Wiggins C., Sankala H., Hogan K. T., Doyle A., Annunziata C. M., Wellons M., Roberts J. D., Sullivan D., Landgren O. & Grant S. (20161213). A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. : Clinical cancer research : an official journal of the American Association for Cancer Research.
Chicago
Holkova Beata, Zingone Adriana, Kmieciak Maciej, Bose Prithviraj, Badros Ashraf Z, Voorhees Peter M, Baz Rachid, Korde Neha, Lin Hui-Yi, Chen Jin-Qiu, Herrmann Michelle, Xi Liqiang, Raffeld Mark, Zhao Xiuhua, Wan Wen, Tombes Mary Beth, Shrader Ellen, Weir-Wiggins Caryn, Sankala Heidi, Hogan Kevin T, Doyle Austin, Annunziata Christina M, Wellons Martha, Roberts John D, Sullivan Daniel, Landgren Ola and Grant Steven. 20161213. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. : Clinical cancer research : an official journal of the American Association for Cancer Research.
Harvard
Holkova B., Zingone A., Kmieciak M., Bose P., Badros A. Z., Voorhees P. M., Baz R., Korde N., Lin H., Chen J., Herrmann M., Xi L., Raffeld M., Zhao X., Wan W., Tombes M. B., Shrader E., Weir-Wiggins C., Sankala H., Hogan K. T., Doyle A., Annunziata C. M., Wellons M., Roberts J. D., Sullivan D., Landgren O. and Grant S. (20161213). A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. : Clinical cancer research : an official journal of the American Association for Cancer Research.
MLA
Holkova Beata, Zingone Adriana, Kmieciak Maciej, Bose Prithviraj, Badros Ashraf Z, Voorhees Peter M, Baz Rachid, Korde Neha, Lin Hui-Yi, Chen Jin-Qiu, Herrmann Michelle, Xi Liqiang, Raffeld Mark, Zhao Xiuhua, Wan Wen, Tombes Mary Beth, Shrader Ellen, Weir-Wiggins Caryn, Sankala Heidi, Hogan Kevin T, Doyle Austin, Annunziata Christina M, Wellons Martha, Roberts John D, Sullivan Daniel, Landgren Ola and Grant Steven. A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20161213.